NAS:ZIOP (USA) Also Trade In: Germany
ZIOPHARM Oncology Inc $ 3.76 0 (0%)
Warning! GuruFocus has detected 3 Severe warning signs with ZIOP. Click here to check it out.
Avg Vol (1m):
Market Cap $:
Enterprise Value $:
Current and historical daily P/E ratio for ZIOP (ZIOPHARM Oncology Inc) from 2005 to Jan 21 2021. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The P/E ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the P/E ratio is positive. Also for stocks with the same P/E ratio, the one with faster growth business is more attractive. ZIOPHARM Oncology stock (ZIOP) PE ratio as of Jan 21 2021 is 0. More Details
ZIOPHARM Oncology PE Ratio (TTM) Historical Data
View and export this data going back to 2005. Start your Free Trial
ZIOPHARM Oncology PE Ratio (TTM) Comparison
|Company||Market Cap(Mil)||PE Ratio (TTM)|
Compare NAS:MTEM NAS:KALA NYSE:KDMN NAS:OYST NAS:RTRX NAS:ADAP NAS:FIXX NAS:ARDX NAS:CARA NAS:REPL OCSE:NOVO B ASX:CSL NAS:VRTX NAS:REGN XKRX:207940 NAS:SGEN NAS:MRNA NAS:ALXN XKRX:068270 NAS:INCY
Address One First Avenue, Parris Building 34, Navy Yard Plaza, Boston, MA, USA, 02129
ZIOPHARM Oncology Inc is a biotechnology company that acquires, develops, and commercializes cancer therapies. Its preclinical and clinical pipeline focuses on treating hematological and solid tumor malignancies using cellular therapeutics. Ziopharm engages in gene therapy systems with its partner Intrexon and collaborators at the University of Texas. To fund the development of its product candidates, the company engages in contractual arrangements with licensing partners both in the United States and abroad.